Concepedia

Kay X. Xiang

KX

Statistics

Publications

4

Citations

1.1K

H-Index

4

Active since

2009

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Novartis (United States)

Kay X. Xiang is an author at Novartis (Switzerland) specializing in chromatin, tumor biology, and gene expression.

Top concepts

Publications per year

2009–2020

4

Publications

4

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

Susan Wee, Zainab Jagani, Kay X. Xiang et al. · Cancer Research · 2009 · 451 citations

Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers

Gregory R. Hoffman, Rami Rahal, Frank P. Buxton et al. · Proceedings of the National Academy of Sciences · 2014 · 405 citations · Full text

Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers

Julien P. N. Papillon, Katsumasa Nakajima, Christopher D. Adair et al. · Journal of Medicinal Chemistry · 2018 · 225 citations · Full text

, , +19

The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma

Florencia Rago, GiNell Elliott, Ailing Li et al. · Molecular Cancer Therapeutics · 2020 · 38 citations

1–4 of 4